EFFECTS OF THE DRUG MILDRONATE
Keywords:
Mildronate -γ-butyrobetaine hydroxylase inhibitor – Antiischemic drug – Heart failure – Heart infarction – Brain circulation disorders – Diabetes mellitusAbstract
Mildronate (3-(2,2,2-trimethylhydrazine) propionate; THP; MET-88; meldonium, quaterine) is an anti-ischemic drug developed in the Latvian Institute of Organic Synthesis. Mildronate was designed as a promising inhibitor of carnitine biosynthesis aimed to prevent accumulation of cytotoxic intermediate products of fatty acid beta- oxidation in ischemic tissues and to block this highly oxygenconsuming process. Actually Mildronate is used in several countries in cardiology (treatment of chronic heart ischemic disease, stable angina pectoris, chronic heart failure, functional disorders of heart and vessels, cardiomyopathy, heart infarction), neurology (acute and chronic ischemic brain circulation disorders, decreased work capabilities, physical and emotional overload, recovery period after various diseases), pulmonology (bronchial asthma and obstructive bronchitis), narcology (abstinence syndrome in chronic alcoholism), ophthalmology (hemophthalm and retina haemorrhages of different aetiology, thrombosis of central vein and its branches in retina, diabetic and hypertonic retinopathies). The main mechanism of action of Mildronate is based on carnitine biosynthesis inhibition aimed to prevent accumulation of cytotoxic intermediate products of fatty acid beta- oxidation in ischemic tissues and to block this highly oxygen-consuming process. Alternatively the drug acts via stimulation of the nitric oxide production in the vascular endothelium through a modification of the γ-butyrobetaine and γ-butyrobetaine ester pools. The present review will summarize data on the Mildronate on different indications of the drug and its mechanisms of action.
References
Hwang YC, Bakr S, Ramasamy R, Bergmann SR. Relative importance of enhanced glucose uptake versus attenuation of long-chain acyl carnitines in protecting ischemic myocardium. Coron Artery Dis 2002; 13: 313-318.
Lerch R, Tamm C, Papageorgiou I, Benzi RH. Myocardial fatty acid oxidation during ischemia and reperfusion. Mol Cell Biochem 1992; 116: 103-109.
Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002; 27: 621-636.
Simkhovich BZ, Shutenko ZV, Meirena DV et al. 3-(2,2,2- Trimethylhydrazinium)propionate (THP)--a novel gamma-butyrobetainehydroxylase
inhibitor with cardioprotective properties. Biochem Pharmacol 1988; 37: 195-202.
Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through
carnitine-lowering effect. Trends Cardiovasc Med 2002; 12: 275-279. Review.
Sjakste N, Gutcaits A, Kalvinsh I. Mildronate: An antiischemic drug for neurological
indications. CNS Drug Reviews. 2005; 11: 151-168.
Shutenko ZhV, Meirena DV, Kagan TI, Sjakste NI, Kalvin’sh IIa. Mildronate:
Mechanisms of action, perspective for pathology correction. Khim Pharm Zhurnal 1995; 29: 13-17. (In Russian).
Simkhovich BZ, Meirena DV, Khagi KhB, Kalvin’sh IIa, Lukevits EIa. Biochemical
characteristics of the anti-ischemic action of the new structural analog of gammabutyrobetaine 3-(2,2,2,-trimethylhydrazine)propionate. Farmakol Toksikol 1987a; 50: 100-104. (In Russian).
Hanaki Y, Sugiyama S, Ozawa T. Effect of 3-(2,2,2-trimethylhydrazinium) propionate, gamma-butyrobetaine hydroxylase inhibitor, on isoproterenol-induced mitochondrial dysfunction. Res Commun Chem Pathol Pharmacol 1989; 64: 157-160.
Akahira M, Hara A, Abiko Y. Effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on myocardialderangements induced by hydrogen peroxide in the isolated perfused rat heart. Fundam Clin Pharmacol 1997; 11: 356-364.
Simkhovich BZ, Vitolinia RO, Stivrinia MI, Shutenko ZhV, Meirena DV. Prevention of ischemic myocardial damage by reducing the intracellular free carnitine level. Kardiologiia 1987; 27: 85-88. (In Russian).
Simkhovich BZ, Briede IaL, Ozola RA, Meirena DV, Kalvin’sh IIa, Lukevits EIa. The effect of mildronate on disorders of the cardiac contractile function in rats caused by an excess of free fatty acids and ischemia. Farmakol Toksikol 1990; 53: 27-29. (In Russian).
Asaka N, Muranaka Y, Kirimoto T, Miyake H. Cardioprotective profile of MET-88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts. Fundam Clin Pharmacol 1998; 12: 158-163.
Dhar PK, Grupp IL, Schwartz A, Grupp G, Matlib MA. Reduction of Carnitine Content by Inhibition of Its Biosynthesis Results in Protection of Isolated Guinea Pig Hearts Against Hypoxic Damage. J Cardiovasc Pharmacol Ther. 1996; 1: 235-242.
Hayashi Y, Tajima K, Kirimoto T, Miyake H, Matsuura N. Cardioprotective effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on cardiac dysfunction induced by ischemia/reperfusion in isolated rat hearts. Pharmacology 2000a; 61: 238-243. 16. Ianson TM, Bauman VR, Grom NP, Kienkas IA, Kalvin’sh IIa. Cardioprotective effect of carnitine and its synthetic analog 3-(2,2,2-trimethylhydrazinium) propionate in rats with experimental myocardial infarction Vopr Med Khim 1988; 34: 122-125. (In Russian).
Kirimoto T, Nobori K, Asaka N, Muranaka Y, Tajima K, Miyake H. Beneficial effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts. Arch Int Pharmacodyn Ther 1996; 331: 163-178.
Hayashi Y, Kirimoto T, Asaka N et al. Beneficial effects of MET-88, a gammabutyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur J Pharmacol 2000; 395: 217-224.
Nakano M, Kirimoto T, Asaka N et al. Beneficial effects of MET-88 on left ventricular dysfunction and hypertrophy with volume overload in rats. Fundam Clin Pharmacol 1999; 13: 521-526.
Sakharchuk II, Denisenko GT, Grushko VS, Bodaretskaia OI, Pishchalenko AN. The use of mildronat in heart failure in patients with chronic ischemic heart disease. Vrach Delo 1989; 9: 21-23.
Dudko VA, Koshel’skaia OA, Sokolov AA. The use of mildronat with stenocardia
patients. Vrach Delo 1989; 10: 64-67. (In Russian).
Ol’binskaia LI, Golokolenova GM. Use of mindronate in cardiac insufficiency in patients with ischemic heart disease. Klin Med (Mosk) 1990; 68: 39-42. (In Russian)
Savchuk VI, Novikova EB, Zhemerikina EV, Lobzeva VI, Seregin EO. Experimental and clinical studies of coronary circulation after administrationof mildronate. Kardiologiia 1991; 31: 17-19. (In Russian).
Karpov RS, Dudko VA, Shipulin VM et al. The clinical instrumental evaluation of
treatment efficacy in patients with concomitant atherosclerosis of the coronary, cerebral and peripheral arteries. Ter Arkh 1991; 63: 90-93. (In Russian).
Teplyakov AT, Sankevitch TV, Stepatcheva TA, Mamchur SE. The use of fatty acid betaoxidation inhibitor mildronate as monotherapy or incombination with atenolol in patients with left ventricular dysfunction after myocardial infarction. Kardiologiia 2003; 43: 15- 18. (In Russian).
Serebrovs’ka ZA, Denisenko HT, Serebrovs’ka TV. The effect of the new metabolic preparations rikavit and mildronat on the parameters of the blood acid-base balance in humans with hypoxia. Fiziol Zh 1992; 38: 26-31. Ukrainian.
Sisetskii AP, Artiukh VP, Sakharchuk II, Starodub NF. The characteristics of the action of mildronate (dehydrate 3-(2,2,2-trimethylhydrazine)propionate) on the red blood parameters in heart failure. Eksp Klin Farmakol 1992; 55: 20-21. (In Russian).
Nedoshivin AO, Petrova NN, Kutuzova AE, Perepech NB. Effect of mildronate on life quality of patients with chronic heart failure. Ter Arkh 1999; 71: 10-12. (In Russian).
Serienko IV, Malakhov VV, Naumov VG. Antianginal and antiischemic effectiveness of Mildronate in compklex treatment of patients with ischemic heart disease and stable stress angina pectoris. Atmosfera. Kardiologiya 2005; 2: 43-45.
Zagorodnyi MI, Kazak LI, Svintsitskii AS, Chekman IS. Cardiotropic characteristics of mildronat. Lik Sprava 2005; 3: 71-76. (In Russian)
Chumburidze V, Kikalishvili T, Sulashvili T. Definition of therapeutic effect of
mildronate in patients with chronic heart failure. Georgian Med News 2005; 5: 25-29. (In Russian).
Vinichuk SM. The efficacy of the mildronate treatment of patients with ischemic stroke. Vrach Delo 1991; 7: 77-79. (In Russian).
Enina G, Timofeeva T Egere D, Majore I. Medicinal effects and indications to mildronate application in neuroangiologic practice. Experimental and Clinical Pharmacotherapy (Riga) 1991; 19: 164-171.
Dziak LA, Golik VA. Use of mildronate for the treatment of patients with circulatory encephalopathy against a background of stenosis of major arteries of the head. Lik Sprava 2003; 5-6: 98-101. (In Russian).
Kremerman IB, Priimiagi LS, Kal’vin’sh IIa, Lukevits EIa. Interferon-inducing and antiinfluenzal properties of 3-(2,2,2-trimethylhydrazine)propionate in an experiment. Vopr Virusol 1987; 32: 576-579. (In Russian).
Safonova IS, Dadalova AI, Shuturova NYu et al. Effect of Mildronate used as an adjuvant on immune human system. Experimental and Clinical Pharmacotherapy (Riga) 1992; 20: 67-71. (In Russian).
Kubar OI, Bryantseva EA, Davydova TV, Furgai SM, Bubenyova TV, Kolltygina NV Results of clinical trials of mildronate immunoadjuvant action in vaccination with
inactivated influenza vaccine. Experimental and Clinical Pharmacotherapy (Riga) 1992; 20: 72-75. (In Russian).
Nikolaeva IA, Prokopenko LG. Immunomodulating action of energizing drugs during dosed fasting. Patol Fiziol Eksp Ter 1998; 3: 12-15. (In Russian).
Starchenko AA, Khil’ko VA, Gaidar BV, Khlunovskii AN, Komarets SA. Characteristics of adaptive reactions of the body’s immune system following operations for vascular anomalies. Zh Vopr Neirokhir Im N N Burdenko 1995; 4: 13-16. (In Russian).
Glozman VN, Berenbein BA, Kirmane RE, Pervushina NV, Shur AA, Agranovskii VB. Use of mildronate in therapy of seroresistant syphilis (serologic and immunologic comparisons. Antibiot Khimioter 1991;36: 38-39. (In Russian).
Orlov VA, Sokolova VI, Zamotaev IP, Elagina LV, Zavolovskaia LI. Clinicoimmunologic aspects of using mildronate in patients with bronchopulmonary diseases. Antibiot Khimioter 1990; 35: 47-50. (In Russian)
Karashurov E, Ostrovskij A, Klavinsh I. Tratment of bronchial asthma with Mildronate. Experimental and Clinical Pharmacotherapy (Riga) 1991; 19: 172-178.
Sakharchuk II, Il’nyts’kyi RI. The use of mildronate and trental in treating disorders of hemorheology and the intracardiac hemodynamics in patients with chronic obstructive bronchitis. Lik Sprava 1996; 1-2: 122-125. Ukrainian.
Antonenko LI, Frantsuzova SB, Arshinnikova LL. The effect of mildronate on
erythrocyte membrane permeability in experimental lung pathology. Eksp Klin Farmakol 1992; 55: 33-35. (In Russian).
Lychkova AE, Savchuk VI, Smirnov VM. Experimental gastric ulcer: gastro- and
duodenoprotective effects of sibusol. Bull Exp Biol Med 2004; 137: 34-36.
Logunova LV, Sutulov YuI. Studies on Mildronate effect on the development and heling of stress ulcer stomach injuries in the experiment. Experimental and Clinical
Pharmacotherapy (Riga) 1992; 20: 82-91.
Bogdarin Yu A, Kalvinsh IYa. Effects of carnitine analogue on content of bile lipids in eneterohepatic system of rabbits with cholelithiasis. Vopr Med Khim 1991; 37: 82-84.
Gaudin’ EP, Kise LIa. Modulators of intracellular metabolism in the treatment of diseases of theb internal ear. Vestn Otorinolaringol 1992; 2: 25-28. (In Russian).
Luchikhin LA, Pankova TB, Kakymov MI. Evaluation of effectiveness of treatment of cochleovestibular disorders with mildronate. Vestn Otorinolaringol 1991; 2: 36-40. (In Russian).
Ramazashvili ZI, Kriukov AI, Luchikhin LA. Treatment of peripheral vestibular disorders using endaural phono-electrophoresis of mildronate. Vestn Otorinolaringol 1990; 2: 34- 39. (In Russian).
